Synergy Spine Solutions Announces $30M Financing
The Series A financing was led by a new institutional investor, Amzak Health, and joined by other investors. The proceeds will be used to complete enrollment of Synergy's
Synergy remains at the forefront of addressing the critical need for innovative solutions in cervical disc replacement. Enrollment for the Synergy Disc® 1-level IDE trial was recently completed in
The 2-Level trial will evaluate the safety and effectiveness of the Synergy Disc® artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of degenerative disc disease in subjects that are symptomatic at two contiguous vertebral levels from C3 to C7. This is a multi-center, prospective, non-randomized, historically controlled study that will be conducted on 200 patients at up to 25 sites.
"We are excited about this next chapter of Synergy's growth," said
With this investment,
Synergy Spine Solutions
The Vision of Synergy Spine Solutions is to identify and commercialize innovative spine technologies that help surgeons improve their patients' quality of life and advance the standard of care. The company's flagship product, the Synergy Disc®, is the only device that is designed to restore both motion and alignment to the spine.
Media Contact:
VP of Sales and Marketing
[email protected] | +1 360 991 6300
Logo - https://mma.prnewswire.com/media/2092974/4520283/Synergy_Spine_Solutions_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/synergy-spine-solutions-announces-30m-financing-302048409.html
SOURCE Synergy Spine Solutions
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boliden's mining concession for Laver maintained as appeals rejected
- How to Tell a Legitimate Moving Company From a Rogue One Before You Book
- Realty Income Prices Upsized $875.0 Million Convertible Senior Notes Offering
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share